SCHEMBL117857

SCHEMBL117857

CC1CCCC(OCCO)(C(C)C)C1

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583686 0.91 CYP1A2 (0.34) CYP1A2
SCHEMBL1616027 0.90 TSHR (0.33) CYP1A2
SCHEMBL1617542 0.87 CYP1A2 (0.32) CYP1A2
SCHEMBL2357386 0.85 CYP1A2 (0.33) CYP1A2
SCHEMBL3409194 0.84 CYP1A2 (0.34) CYP1A2
SCHEMBL110176 0.80 CYP1A2 (0.33) CYP1A2
SCHEMBL1617094 0.79
SCHEMBL1617271 0.79
SCHEMBL1617792 0.79 CNR1 (0.30)
SCHEMBL1617802 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240041726-A1 FOAMABLE COMPOSITION, USE THEREOF, AND PROCESS FOR ITS PREPARATION CHATTEM, INC. 2024-02-08 US claimed
EP-4231985-A1 FOAMABLE COMPOSITION, USE THEREOF, AND PROCESS FOR ITS PREPARATION Chattem, Inc. (US) 2023-08-30 EP claimed
WO-2022087343-A1 FOAMABLE COMPOSITION, USE THEREOF, AND PROCESS FOR ITS PREPARATION CHATTEM, INC. (US) 2022-04-28 WO claimed
US-20210212983-A1 ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS CHICAGO ATLANTIC ADMIN, LLC 2021-07-15 US claimed
EP-3169365-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH Westfälische Wilhelms-Universität Münster (DE) 2017-05-24 EP claimed
EP-1924148-B1 CONFECTIONERY COMPOSITION INCLUDING AN ELASTOMERIC COMPONENT, A COOKED SACCHARIDE COMPONENT, AND A SENSATE INTERCONTINENTAL GREAT BRANDS LLC (US) 2016-07-20 EP claimed
US-20160128944-A1 COATED PARTICLES AND COMPOSITIONS COMPRISING SAME VYOME THERAPEUTICS LIMITED (IN) 2016-05-12 US claimed
US-9320705-B2 Sensation modifying topical composition foam FOAMIX PHARMACEUTICALS LTD. (IL) 2016-04-26 US claimed
EP-3003031-A1 COATED PARTICLES AND COMPOSITIONS COMPRISING SAME Vyome Biosciences Pvt Ltd (IN) 2016-04-13 EP claimed
WO-2015169884-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) 2015-11-12 WO claimed
EP-1215257-B1 Fragance composition TAKASAGO PERFUMERY CO LTD (JP) 2009-10-21 EP claimed
US-20080253973-A1 SENSATION MODIFYING TOPICAL COMPOSITION FOAM FOAMIX LTD. (IL) 2008-10-16 US claimed
EP-1973422-A1 COMPOSITIONS PROVIDING A HEATING SENSATION FOR ORAL OR DERMAL DELIVERY Cadbury Adams USA LLC (US) 2008-10-01 EP claimed
WO-2007126430-A1 COMPOSITIONS PROVIDING A HEATING SENSATION FOR ORAL OR DERMAL DELIVERY CADBURY ADAMS USA LLC (US) 2007-11-08 WO claimed
US-20070178123-A1 FLAVOR-ENHANCING COMPOSITIONS, METHOD OF MANUFACTURE, AND METHODS OF USE KRAFT FOODS GLOBAL BRANDS LLC 2007-08-02 US claimed
US-20070148103-A1 Compositions providing a heating sensation for oral or dermal delivery CADBURY ADAMS USA, LLC. 2007-06-28 US claimed
US-6838106-B2 Warming composition for food and drink or for oral care preparation TAKASAGO INTERNATIONAL CORPORATION (JP) 2005-01-04 US claimed
US-6673844-B2 REDUCING SKIN SENSITIVITY TAKASAGO INTERNATIONAL CORPORATION (JP) 2004-01-06 US claimed
US-20020142015-A1 Warming composition TAKASAGO INTERNATIONAL CORPORATION 2002-10-03 US claimed
EP-1215257-A2 Warming composition Takasago International Corporation (JP) 2002-06-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070148103-A1 Compositions providing a heating sensation for oral or dermal delivery TAS2R8, TAS2R60, TAS2R20 CYP1A2 2289/4885
US-20020142015-A1 Warming composition CUTA, TRPA1, POLR1C CYP1A2 135/4885
US-20080253973-A1 SENSATION MODIFYING TOPICAL COMPOSITION FOAM TRPA1, GPR35, TRPV1 CYP1A2 1644/4885
US-20210212983-A1 ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS CNR2, CNR1, CPNE4 CYP1A2 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.